SCHEMBL4430165

SCHEMBL4430165

CCOCCCNC(=O)c1ccccc1C1CCN(CCN2C=COC(C3=CC=CC(=O)C3)=C2)CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 3/20 0.38
POLB P06746 1/20 0.36
UTS2R Q9UKP6 2/20 0.36
TSHR P16473 1/20 0.35
HRH2 P25021 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
DRD3 P35462 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
TP53 P04637 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890241 0.94 HPGD (0.37) HPGDUTS2RKMT2ADRD2HTR2A
SCHEMBL4430408 0.91 UTS2R (0.37) HPGDPOLBUTS2RDRD2HTR2A
SCHEMBL4440078 0.91 UTS2R (0.36) UTS2RDRD2HTR2ADRD3HDAC3
SCHEMBL4433580 0.90 HDAC3 (0.36) HPGDPOLBUTS2RTSHRMEN1
SCHEMBL4891155 0.89 UTS2R (0.36) UTS2RMEN1KMT2ADRD3HDAC3
SCHEMBL15808512 0.88 EPHX2 (0.37) HPGDHTTTSHRNPC1ALDH1A1
SCHEMBL4890309 0.88 BCL3 (0.35) UTS2RMEN1KMT2ADRD3HDAC3
SCHEMBL4437169 0.88 UTS2R (0.41) LMNAUTS2RDRD2HDAC3HDAC1
SCHEMBL4432414 0.88 ASAH1 (0.39) HPGDPOLBTSHRMEN1KMT2A
SCHEMBL4885280 0.87 STAT3 (0.37) HPGDPOLBUTS2RMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US claimed
EP-2049120-A1 UROTENSIN II RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2009-04-22 EP claimed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US claimed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 HPGD 1252/4885HTT 702/4885LMNA 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.